A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
about
Anakinra for rheumatoid arthritisSafety of extended treatment with anakinra in patients with rheumatoid arthritisThe role of osteoprotegerin in arthritisSerum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanerceptHormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritisInterleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activityTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesMyeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts.Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.Anakinra treatment of patients with rheumatoid arthritis.Promising bone-related therapeutic targets for rheumatoid arthritis.Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment.Bone damage in rheumatoid arthritis: mechanistic insights and approaches to preventionRole of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis.The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis.Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages.Caspase functions in cell death and disease.Cooperative role of tumour necrosis factor-α, interleukin-1β and neutrophils in a novel behavioural model that concomitantly demonstrates articular inflammation and hypernociception in mice.Interleukin-1 receptor antagonist as therapy for inflammatory disorders.Anticytokine therapy for osteoarthritis.Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta.Advances in the treatment of rheumatoid arthritis: old versus new therapies.Rheumatoid arthritis: developing pharmacological therapies.Blocking interleukin-1 in rheumatic diseasesUpdated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.Osteoporosis in the rheumatic disease patient.Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis).Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.Gene therapy for arthritis.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesTargeting cytokines in autoimmunity: new approaches, new promise.Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis.An expanding role for interleukin-1 blockade from gout to cancer.Increased synovial expression of nuclear receptors correlates with protection in pristane-induced arthritis: a possible novel genetically regulated homeostatic mechanism.The role of IL-1β in the bone loss during rheumatic diseases.Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
P2860
Q24241707-67A834CB-E6B8-4F2A-89D5-CD6E03A33D2EQ24675209-F2FFEB36-4FC2-41EF-A45B-4D21BC3399B6Q24797889-B10E6740-208F-407A-BFAF-BEC1477F1055Q24804764-9CDC4022-967D-48D6-83BD-75AFD25B3BB6Q24804802-A328BA0D-A1FD-4DF5-85C6-3B71E996CAB7Q24805600-C1A4A882-CCD4-4BC8-9DAA-D253255797D0Q24813092-AC5CA41D-4AD4-4B61-BBF2-59484EE143FDQ26799747-63AA4A7B-713F-4D02-B2A7-080690966FEFQ30278787-2AADE82B-370A-4FEB-AFEB-8242CBBE4C83Q30739084-3B9DEE24-C227-493E-BA65-61D5B260007DQ30863549-DF01CC93-EB8F-4131-9748-99688F172AACQ31089069-D76450A1-2CE4-41FB-AADA-E61C76F99652Q33554023-86992709-A827-4230-8C26-20D1A82A8B03Q33896725-DE31C843-A321-4031-90B2-580B220DE441Q34001621-F4E656F5-0C54-4B32-ACFE-46847EBD1F7DQ34071325-C6798E2C-A002-4A9E-8F36-F3CB7773A909Q34122715-CB9E3822-2A93-4ED0-B306-0E38715B5999Q34335747-4C7005B3-342A-4928-BFFC-473E0D629EB1Q34336335-423B49A4-B1C0-46B6-AE7B-27D07EF7BE49Q34449716-F58A4CE7-A519-4F19-AADC-886C8489ED0FQ34452084-58467E39-606D-4896-881C-5B8E5B219731Q34452635-90287A11-66B9-4F5F-AB5A-409117385EBDQ34467768-C7FDB945-4EA5-4251-AE40-3AC94C0A2CC6Q34706876-32916F07-5FDD-4913-AB3D-8551875FD2A0Q34706975-400466A8-D510-487F-8E54-12F157008EBDQ34822708-C7A4BFC5-18FE-4FD8-9256-F5EE6BDF5BCDQ34962946-3F8D0407-B0F4-454F-8016-BD45F623E138Q34963124-2D687535-F10F-4565-9916-16DCA3671352Q34986976-00FD1EEF-98FC-4E38-9F0E-EEDCC540CEFCQ35040784-EC34E728-EB86-4C14-8B54-8AADBA11E8C4Q35083436-48447A56-138F-4729-B1E0-668EAF021091Q35122176-0151B87F-6E20-4900-A1E4-EDEA718EABE8Q35133812-7745E853-98DC-49CD-880E-09570B9B4EB3Q35144028-42C4E420-729E-45FE-958D-26B6E20C157FQ35194346-4051BF18-7D03-4BD6-B2FD-9B41C80C64B8Q35219001-A8A7AEB3-EC6B-446D-B7FE-561DAA62FB4CQ35243488-D13CB941-1012-47AC-ACBC-E7759632527EQ35540844-AADE4D18-0444-417D-9DFF-EC4F08B3C443Q35551774-DB1BF7C2-65AD-411F-9542-CC88202ABBAAQ35553451-6229C0FC-3518-402E-80A2-8A75BBBE5D68
P2860
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
A multicenter, double-blind, d ...... n of Genant and Larsen scores.
@en
type
label
A multicenter, double-blind, d ...... n of Genant and Larsen scores.
@en
prefLabel
A multicenter, double-blind, d ...... n of Genant and Larsen scores.
@en
P2093
P1476
A multicenter, double-blind, d ...... n of Genant and Larsen scores.
@en
P2093
Aitchison R
Bresnihan B
P304
P356
10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P
P577
2000-05-01T00:00:00Z